Primary and secondary outcome measures
depressive, incident mental disorders, disability, anxiety
EMA
In this trial, changes in depressive, anxiety, and stress symptoms (assessed with the DASS-21 at the respective main assessment) in the intervention vs. control group from baseline to post were defined as the primary outcome of the intervention efficacy. Rates of incident mental disorders in the intervention vs. control group from entry exam to follow-up were defined as the primary outcome of the prevention efficacy. Findings for these outcome measures have been previously presented [Secondary outcomes of the intervention efficacy included changes in other symptom measures (e.g., those assessed with the DSM-5 Level 2 Cross-Cutting Symptom Measures at the respective main assessment and symptom measures assessed via EMA) and clinical changes (e.g., number of symptoms and diagnoses, impairment, and disability) in the intervention vs. control group from baseline to post. Secondary outcomes of the prevention efficacy included changes in depressive, anxiety, stress, and other symptoms as well as clinical changes in the intervention vs. control group from post to 12-month follow-up. No important changes to the methods or trial outcomes were made after trial commencement.